BR112022021420A2 - Tratamento de condições associadas a hormônios tireoidianos - Google Patents

Tratamento de condições associadas a hormônios tireoidianos

Info

Publication number
BR112022021420A2
BR112022021420A2 BR112022021420A BR112022021420A BR112022021420A2 BR 112022021420 A2 BR112022021420 A2 BR 112022021420A2 BR 112022021420 A BR112022021420 A BR 112022021420A BR 112022021420 A BR112022021420 A BR 112022021420A BR 112022021420 A2 BR112022021420 A2 BR 112022021420A2
Authority
BR
Brazil
Prior art keywords
conditions associated
treatment
thyroid hormones
compositions
treating
Prior art date
Application number
BR112022021420A
Other languages
English (en)
Inventor
O Scott Linzy Iii
Original Assignee
O Scott Linzy Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O Scott Linzy Iii filed Critical O Scott Linzy Iii
Publication of BR112022021420A2 publication Critical patent/BR112022021420A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

TRATAMENTO DE CONDIÇÕES ASSOCIADAS A HORMÔNIOS TIREOIDIANOS. São divulgados métodos e composições para tratar e prevenir condições médicas associadas à distribuição, transporte e desiodinação do hormônio tireoidiano no sistema nervoso central ("SNC"), incluindo, entre outras, ao cérebro e à medula espinhal. Em particular, são divulgados métodos e composições para o tratamento da Síndrome de Allan Herndon Dudley.
BR112022021420A 2020-04-22 2021-04-22 Tratamento de condições associadas a hormônios tireoidianos BR112022021420A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063013960P 2020-04-22 2020-04-22
US202063088523P 2020-10-07 2020-10-07
US202163135118P 2021-01-08 2021-01-08
PCT/US2021/028675 WO2021216896A1 (en) 2020-04-22 2021-04-22 Treatment of conditions associated with thyroid hormone

Publications (1)

Publication Number Publication Date
BR112022021420A2 true BR112022021420A2 (pt) 2022-12-27

Family

ID=78270024

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021420A BR112022021420A2 (pt) 2020-04-22 2021-04-22 Tratamento de condições associadas a hormônios tireoidianos

Country Status (11)

Country Link
US (1) US20230149410A1 (pt)
EP (1) EP4138809A4 (pt)
JP (1) JP2023522956A (pt)
KR (1) KR20230015906A (pt)
CN (1) CN115916177A (pt)
AU (1) AU2021260956A1 (pt)
BR (1) BR112022021420A2 (pt)
CA (1) CA3175608A1 (pt)
IL (1) IL297453A (pt)
MX (1) MX2022013140A (pt)
WO (1) WO2021216896A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015762A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC Methods and formulations for gene therapy, and for combining gene therapy with ditpa treatment, of allan-herndon-dudley syndrome
WO2024015765A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC Methods for treating allan-herndon-dudley syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1320776B1 (it) * 2000-08-07 2003-12-10 Giampiero Valletta Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie
CN102639009B (zh) * 2009-07-10 2016-01-20 林齐·O·斯科特三世 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物
WO2012171065A1 (en) * 2011-06-17 2012-12-20 Esra Ogru Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa).
WO2016101017A1 (en) * 2014-12-24 2016-06-30 Neuorphan Pty Ltd Improvements in oligodendroglial cell culturing methods and in methods for treating neurodegenerative disorders by using thyroid hormones or analogues
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease

Also Published As

Publication number Publication date
US20230149410A1 (en) 2023-05-18
AU2021260956A1 (en) 2022-11-17
KR20230015906A (ko) 2023-01-31
CN115916177A (zh) 2023-04-04
CA3175608A1 (en) 2021-10-28
EP4138809A4 (en) 2024-05-01
IL297453A (en) 2022-12-01
MX2022013140A (es) 2022-11-16
WO2021216896A1 (en) 2021-10-28
EP4138809A1 (en) 2023-03-01
JP2023522956A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
BR112022021420A2 (pt) Tratamento de condições associadas a hormônios tireoidianos
MX9205681A (es) Aminometil-cromanos, procedimiento para su fabricacion y medicamento que los contiene.
Sojka et al. Escherichia coli serotypes associated with certain pig diseases
CU23111A3 (es) Moduladores del receptor glucocorticoide
DK0798968T3 (da) Middel til at forbedre produktionen og avlen af produktionsdyr inden for fjerkræsindustrien
ES2038122T3 (es) Un procedimiento para la preparacion de una composicion veterinaria2.
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
ES2133714T3 (es) Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares.
Shea et al. What can you do to protect the newborn brain?
NZ728284A (en) Treatment and prevention of the common cold using povidone-iodine
ES2103733T3 (es) Procedimiento para combatir el piojo de los peces.
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
BR8707751A (pt) Aperfeicoamento em aparelhos para produzir material para haste de filtro a partir de uma estopa fibrosa e elemento de conduto
Pal et al. A comparative study between oral pregabalin and gabapentin in prolongation of postoperative pain relief after spinal anesthesia
DK1043028T3 (da) Phytase til forebyggelse eller behandling af mastitis
BR112018016874A2 (pt) métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)
CN215019598U (zh) 一种兽医治疗用保定架
BR9915899A (pt) Composto, composição farmacêutica e método para tratar ou inibir distúrbios associados com contração do músculo liso.
HK1042238A1 (en) Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
BR112021024927A2 (pt) Éster isopropílico de ácido [((1r,2s,5r)-2-isopropil-5-metil-ciclo-hexanocarbonil)-amino]-acético para tratamento de tosse crônica
Shenberger MD Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial
Meguig et al. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Kaur et al. Effects of low dose methamphetamine in a Drosophila melanogaster model of traumatic brain injury (TBI)
AR122344A1 (es) Uso de reboxetina para tratar desórdenes del sistema nervioso
BR112022016304A2 (pt) Métodos de prognóstico terapêutico.